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The first fifty years ofthe Connecticut Tumor Registry (1935-1985) have seen unprecedented
progress in the collection of standardized data on cancer patients and in the processing of these
data, from paper documents to punch cards and magnetic tapes. The need for collecting such
information was first recognized, in the early 1930s, by a group ofphysicians, health profession-
als, and laymen in New Haven who observed alarming increases in cancer rates and poor survival
ofcancer patients in this city. This paper recalls the growth and development ofthe registry and
the role played by the Connecticut legislature, the State Medical Society, the Connecticut
Department of Health, and the National Cancer Institute in this process. For halfa century, the
registry has provided assistance to practitioners, hospitals, and research scientists, not only in
Connecticut but across the country and around the world. By making available reliable data on
incidence and survival, the registry has played a key role in patient management, clinical trials,
and etiologic studies. It has also demonstrated the value and served as an exemplary model of a
population-based registry. At this juncture in its history, prospects for the future of the
Connecticut Tumor Registry appear bright. Its data base will be an essential resource for the
recently established Cancer Control Research Unit (CCRU) in the state and for new intervention
studies by investigators at Yale, the University of Connecticut, and the State Health Depart-
ment.
In the early 1930s, a group of concerned physicians, health professionals, and
laymen in New Haven found alarming cancer trends in this city. They reported an
increase in cancer mortality from 66 to 180 per 100,000 population between 1900 and
1934, showing that New Haven had one ofthe highest cancer mortality rates in New
England [1]. They also noted that, among patients hospitalized for cancer, fewer than
20 percent would survive longer than five years. This group, under the name ofCancer
Committee of New Haven, initially chaired by Dr. Ira Hiscock, Professor of Public
Health at Yale, assisted physicians and hospitals in New Haven with the collection of
uniform data on the registration and follow-up ofcancer patients.
The committee soon drew statewide recognition for its important work and, in May
1933, the State Medical Society appointed the first TumorStudy Committee, with Dr.
Thomas H. Russell aschairman [2]. In 1935, this committeeorganized the Association
ofTumor Clinics, which was chaired by Dr. Charles L. Larkin. With active support of
hospitals and their staffs, the Tumor Study Committee was instrumental in passage by
the Connecticut General AssemblyofSenate Bill 101 in June 1935 [3]. This bill, which
led toward the establishment of the Connecticut Tumor Registry (CTR), authorized
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the State Board of Health "to make investigation concerning cancer, the prevention
and treatment thereofand the mortality therefrom... ." The legislature also allocated
$10,000 in 1935 to enable the State Board of Health to carry out a cancer program in
Connecticut, this money to be used from July 1, 1935, to June 30, 1937. In addition,
the sum of $6,683.00 was allotted in 1936 by the federal government under Title VI,
Public Health Service Section ofthe Social Security Act, to beused in cancer activities
[4].
With the new legislation, the Connecticut State DepartmentofHealth, in December
1935, moved tocreatethe Division ofCancer Research as a new unitofthe Preventable
Disease Section. Dr. Matthew Griswold, Chief of the Division of Cancer and Other
Chronic Diseases, was appointed to direct the educational and statistical research
programs. Significantly, the former Executive Secretary of the New Haven Cancer
Committee, Herbert F. Hirsche, was engaged as Research Statistician in the new
cancer division. Both Dr. Griswold and Mr. Hirsche weregraduates ofthe Department
of Public Health at Yale University [5].
Although congressional attention to the issue of cancer control in the U.S.A. was
reported as early as 1927, the National Cancer Institute Act (Public Law 244) was not
signed until ten years later, in 1937, by President Franklin D. Roosevelt, to set in
motion a federal commitment to cancer control [6].
The new Division of Cancer Research in the Connecticut State Department of
Health worked closely with the State Medical Society's Tumor Study Committee
which, in 1949, adopted its current name, the Cancer Coordinating Committee. In the
years between 1935 and 1941, it carried out analyses ofmortality statistics, assisted in
the establishment oftumor clinics, and facilitated legislative activities.
The 1935 legislation authorized the State Department of Health to investigate
cancer and set aside money to pay hospitals for reporting. This had the effect of
initiating a comprehensive statewide cancer reporting system. Money was deemed
more important than a reporting requirement. The funds made available sufficed to
support a registry staff in the Health Department and, equally important, to pay the
salary of a tumor clinic secretary in each Connecticut hospital. The sponsors were
primarily interested in patient survival data; incidencedata weresecondary. This is not
surprising; cancer epidemiology was then in its infancy. There were no population-
based cancer registries, and the first cancer morbidity survey undertaken by the
National Cancer Institute (NCI) wasjustgetting under way [7]. The first case-control
studies on smoking and lung cancer would not be reported for another ten years [8,9].
The sponsors probably realized that direct support for secretaries to service the
hospital clinics and tumor registry ensured that someone in each of the 28 to 30
hospitals then in existence in Connecticut would be on hand to take care ofthe records
and do the necessary patient follow-up. The key reporting unit was the hospital, not the
individual physician. So long as there were direct dealings between the hospitals and
the cancer registry, concern about protecting the confidentiality of patients' records
was not a major issue at that time.
In 1941, a team from the State Division ofCancer Research visited each participat-
ing hospital and made abstracts of the records of each cancer patient admitted to the
hospital, beginning with January 1935. During these visits, the tumor clinics' secretar-
ies were trained to carry out the case registration functions. The key element which
made the tumor registry a going concern was the provision offinancial support for each
hospital's tumor clinic secretary. By December 1942, 22 hospitals, comprising over 90
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percent of the hospital beds in Connecticut, were reporting. The remaining hospitals
were contacted thereafter, and arrangements were made to incorporate them into the
new registry system [10].
A reporting system that covered hospitalized patients only would have missed that
fraction of patients not admitted to hospitals. This made it necessary to match all
Connecticut death certificates which mentioned cancer against the case reports from
hospitals in order to ascertain the fraction of deaths not previously reported as cases.
From its inception, the registry routinely secured copies of death certificates from the
Bureau of Vital Statistics. Over the years, the proportion of cancer deaths not
previously reported as cases fell from a high 37 percent in the first six years of the
registry to 1.3 percent in the late 1970s [11,12].
At the registry's inception, the plan was to report all cases of cancer first diagnosed
on and after 1 January 1935. This ambitious goal was achieved despite complications
encountered during World War II. The tumor registry's statistician, Mr. Hirsche, who
held a commission in the army reserves, was called to active duty and never returned to
the registry. He was replaced during the war years by Eleanor J. MacDonald, who was
a research statistician in the Division of Cancer and Other Chronic Diseases.
Recruitment of registry staff was difficult. Ms. MacDonald tackled all the problems
with enthusiasm and was most effective in motivating tumor registry secretaries and
hospital staffs to supply reports.
In April 1947, Dr. William Haenszel, from the Division of Vital Statistics, New
York State Health Department, joined the staff of the Connecticut State Health
Department as Director of the Bureau of Vital Statistics. The following notes record
some of his personal recollections.
"By 1949, a substantial backlog of records awaited processing, and physicians were
requesting assistance for ad hoc studies. This situation was further complicated by
staffshortages. There was a need to move from the registry's development phase to the
establishment of data processing routines on a current basis. Ms.MacDonald left the
registry to accept an appointment as Professor of Epidemiology at M.D. Anderson
Hospital in Texas. Prior to that time, I had no direct involvement in the management of
the tumor registry, although I was aware of its activities and of the support it was
getting from the State Medical Society. I remember that Dr. Griswold attended
regularly the meetings of the State Medical Society's Tumor Study Committee,
perhaps as often as once a month or every other month. I also recall the names of two
physicians who were key participants in State Medical Society committees and keenly
interested in working with the registry data-Drs. E.J. Ottenheimer and A.W.
Oughterson. They were particularly interested in the survival ofpatients with cancer of
the rectum [13]. This was a time when a more aggressive approach to rectal cancers,
including dissection of the anus and rectum with colostomy, was being introduced.
They were seeking evidence from registry data for improved survival of patients with
rectal cancer.
"When Ms. MacDonald left the registry, the Commissioner of Health, Dr. Stanley
Osborn, asked me to confer with Dr. Griswold and advise him on recruiting a
replacement. Data management was the main concern. Dr. Griswold and I needed
advice from someone experienced in large-scale processing ofcancer patient data. The
NCI's second national cancer morbidity survey of 1947-1948, headed by Harold Dorn,
Ph.D., [14] was nearing completion, and we approached him for assistance. Dr. Dorn,
Chief ofthe Biometric Section, NCI, sent Dr. Sidney J. Cutler, analytic statistician in
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his section, to review the registry's operations. One should remember that the postwar
years were those of transition in data management, ranging from hand files, keysort
cards, punch cards, and the use of printing tabulators. Dr. Cutler provided sound
advice and, in effect, ushered in the era of data management. Dr. Earl Pollack was
recruited from the New York State Department of Health to replace Ms. MacDonald
and, with the assistance ofCharles S. Wilder, he implemented Dr. Cutler's recommen-
dations and brought the data management and processing elements of the registry
under good control.
"In 1952, Dr. Dorn recruited me as his replacement at theNCI Biometry Branch, so
I became head of a consulting unit which I had earlier dealt with while acting in a
different capacity. This sequence of events laid the foundation for the sustained
collaboration between the Connecticut Tumor Registry and the NCI in later years.
"With the completion of the data management phase, it became time to focus
attention on data analysis. Dr. Cutler, who continued to serve as a consultant to the
registry, and I participated in the preparation of a monograph entitled Cancer in
Connecticut: 1935-1951, which was published in 1955 [15]. This publication of
registry data, based on a standardized format for tabulations, resulted from many
discussions with and suggestions by Drs. Griswold and Pollack and Mr. Wilder. It
would be hard to overestimate the significance of this report, which set the pattern for
subsequent systematic publications of incidence and survival data by the Connecticut
Tumor Registry. It established the registry's reputation as the prime American data
source on cancer incidence and patient survival. This monograph reported data for
three time periods: 1935-40 (early developmental years); 1941-46 (war years);
1947-51 (mature phase). It also reported patient survival data by hospital size. There
was at the time great interest in comparing the experiences of small community
hospitals with those ofthe large, tertiary care centers.
"After the Connecticut monograph was published, there was a changing of the
guard in the tumorregistry. Dr. Henry Eisenberg, who had been working on a federally
supported Venereal Disease Program, replaced Dr. Griswold on his retirement as
Director ofthe Division ofCancer and Chronic Diseases. Richard Greenberg, who was
on the staffofthe registry, became ChiefStatistician, replacing Dr. Earl Pollack, who
took a position at the National Institutes of Health.
"In 1956, I received a phone call from Dr. Colin White, Professor of Biostatistics at
Yale University. He referred to a recent Yale medical school graduate, then complet-
ing an internship, who had written a senior thesis on methodolgical aspects of
epidemiological studies. Could the NCI Biometry Branch find a spot for him? The
branch did have an opening for a commissioned officer in the Public Health Service
and John C. Bailar III, M.D., became linked to the history ofthe Connecticut Tumor
Registry. Dr. Bailar was assigned to New Haven for about two years, where he worked
with the registry materials in Hartford and in the New Haven hospitals. He
collaborated with Dr. Ira Goldenberg, a New Haven surgeon and Yale professor, in a
breast cancer study and contributed a note on the follow-up of lost cancer patients
published in NCI Monograph 6 [16]. Dr. Bailar also participated in a comparative
study of the survival of cervical cancer patients in Connecticut and the southwest
region ofEngland and Wales. This study was stimulated by the fact that much poorer
survival experience from cancer was observed in New England when data from the two
population-based registries were compared. This project involved visits by two
pathologists to all hospitals in the two regions to review, according to protocol, the
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pathologic characteristics of all cervical cancer cases diagnosed in a specific time
period. This particular exercise demonstrated the unique capabilities of the Connecti-
cut Tumor Registry for these special studies carried out by Dr. Bailar with staff
support. The close liaison between the registry and hospitals, reinforced by the
presence of tumor registry secretaries in each hospital, successfully met all the
logistical demands ofthe traveling team ofpathologists. The findings were published in
NCI Monograph 19 [17].
"The history of the Connecticut Tumor Registry was profoundly influenced by an
event that took place at NCI. The research program in cancer treatment under the
auspices of the Cancer Chemotherapy National Service Center (CCNSC) needed
baseline data on patient survival to supplement data generated by clinical trials in
evaluating the effects of new therapies. No systematic national data on site-specific
cancer patient survival existed as of 1955. Dr. Michael Shimkin, Chief of Biometry
Branch, NCI, proposed that a group of hospital-based registries and some population-
based registries (including Connecticut) prepare a standard set of tabulations and
report the findings at the 1956 National Cancer Conference in Detroit. The presenta-
tion ofdata wasjudged a success, leading to the proposal that the registries report their
updated findings at the 1960 National Cancer Conference in Minneapolis. At
meeting ofregistry representatives, I proposed that the tabulations be replaced by a set
of uniform punch cards. This led to the formation of the End Results Group (ERG),
which not only reported their findings at Minneapolis but stayed together to publish
their findings for many years thereafter. The Connecticut data played an important
role in establishing the baseline experience of all cancer patients for comparison with
the results from the specialized, tertiary care institutions. In these early years, the
registry's participation in the NCI-sponsored End Results Group was subsidized for
out-of-pocket costs by the Connecticut Department of Health. The Connecticut data
were also valuable for delineating trends in survival rates in Connecticut and
California (NCI Monograph number 6) [18].
"Following the adoption of uniform punch cards for recording data, the staff in the
Connecticut registry made important contributions to the ERG procedures manual by
providing instructions for coding, editing, consistency checks, and other data manage-
ment operations.
"In the late 1950s, Dr. Franklin Foote was Commissioner of Health. The staffof the
registry then included Dr. Eisenberg, Director of the Division of Cancer and Chronic
Diseases; R. Greenberg, Chief Statistician; Jack R. Keough, Registry Director; and
Patricia Campbell, Tumor Registry Supervisor.
"The Connecticut registry indirectly influenced the interpretation of data from the
clinical trials of leukemia chemotherapy. Dr. Cutler repeatedly brought to the
attention of Dr. Zubrod, at the NCI, and other clinical investigators, that the results of
clinical trials describing dramatic treatment effects were not being reflected in the
experience of the general population as observed in the Connecticut registry.
Continued reference to the Connecticut data tended to moderate the interpretation of
the clinical trial findings.
"In addition to its participation in ERG, the Connecticut registry was a charter
contributor to the first volume of Cancer Incidence in Five Continents [19] and has
provided current data in all subsequent editions. Dr. Eisenberg was a member of the
editorial committee that advised on the format for the initial publication.
"Standard actuarial procedures, described by Berkson and Gage [20], and Ederer,
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Axtell, and Cutler [211, have been used for the analysis of patient survival data
collected by the Connecticut registry. The long time span covered by the registry and
the volume ofavailable patient material encouraged liberal use ofthe interval survival
ratio in data analysis. This concept involves comparison of the patient experience for
specified intervals after diagnosis with the overall mortality experience for the general
population oflike age and sex composition.
"Papers reporting the long-term survival experience for breast, uterine, and ovarian
cancers were published in 1959 and 1960 by Cutler, Ederer, Griswold, and Greenberg
[22,23,24]. Papers utilizing the interval survival ratio documented that breast cancer
patients never returned to the experience of the general population (ISR = 1.0) even
15 years or more afterdiagnosis. This pattern deviated markedly from the colon cancer
experience, where patients surviving ten years returned to the general population
experience [25]. The unfavorable experience for breast cancer patients was due
primarily to continued high mortality from this cancer.
"In view ofcoverage ofincidence data dating back to 1935, the Connecticut registry
was in a very good position to report on trends in site-specific cancer incidence. The
other U.S. sources of information were the two first cancer morbidity surveys in
1937-39 and 1947-48 [7,14], but these werecertainly'inferior to the Connecticut data.
The Connecticut data clearly indicated the major changes in risk, the rise in male and
female lung cancer, the decline in stomach cancer, etc. Given the predominantly white
population of Connecticut, the registry did not supply useful data on blacks. In the
early years of the registry, no examples can be cited of its ability to detect changes in
risk for specific site-histology complexes. The latter had to await a more refined
morphological classification of tumors contained in theStandardized Nomenclature of
Pathology (SNOP) and adapted for tumor registries by an American Cancer Society
committee [26]. However, according to Dr. John Berg, the Connecticut registry did
signal the rise in mesotheliomas after World War II. This could have been detected
sooner if someone had been looking for it.
"Other uses of the Connecticut data stimulated methodological developments. For
example, Ederer, Myers, and Mantel examined the distribution of leukemia cases for
169 Connecticut towns over 15 years and proposed a test for the detection of
space-time clusters of cases [27]. The test for clustering of leukemia cases was
negative, but it is interesting to note that, when applied to known infectious diseases in
Connecticut, such as poliomyelitis and hepatitis, the test was positive.
"In the 1960 decade, the data management activities of the Connecticut Registry
were under good control. What was missing was the utilization of the registry for
special studies. The rather inflexible Connecticut civil service personnel system made it
difficult to writejob classifications for research investigators, and the Health Depart-
ment could not recruit such individuals. The problem was compounded by the
departure of Dr. R. Greenberg, who had completed his work for a Ph.D. at Yale
University. To fill thevoid created by his departure, the NCI assigned Roger Connelly,
from its Biometry Branch, to the staffofthe Connecticut Tumor Registry. He worked
closely with Dr. Eisenberg and with him published a series of papers reporting the
registry findings [10,28] until Dr. Eisenberg's death in 1968. At this time, Dr. Barbara
Christine became chief of the Chronic Diseases Division and remained in office until
she died of cancer in 1975. She published, in collaboration with her staff, a series of
Connecticut Health Department monographs on cancer in Connecticut in the 1960s
and reported on cancer incidence, mortality, and survival in Connecticut during this
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period [29]. She was assisted by J.T. Flannery, who joined the registry in 1962 and
became director in 1975. His management ofthe registry has remained, until this day,
an example of efficiency and dedicated effort.
"In the late 1960s, a data management problem arose to complicate the effective
participation of the Connecticut registry in the End Results Group. The state
government committed itself to the establishment of a centralized computer center to
service all departments ofstate government. Even though the NCI contract covered all
data processing costs, the Connecticut registry was prevented from establishing its own
computer unit. While the difficulties caused by this inflexible computer processing
arrangement have improved over time, the Connecticut Tumor Registry does not, to
date, have it own computer facilities.
"Early in the 1970s a budget crisis in the Connecticut state government intervened
to threaten further supply of data to the End Results Group. To cope with this deficit,
the governor proposed eliminating payments to the hospital tumor registry secretaries
and making the reporting of cancer cases compulsory, thus shifting the costs to the
individual hospitals. A statute was passed mandating that cancer become a reportable
disease effective March 23, 1971 [30]. This turn ofevents posed a dilemma to the NCI.
Connecticut's participation in the End Results Group met important national goals.
Experience elsewhere had shown that loss of funding for essential support services
inevitably led to the demise of a cancer registry. The risk to the End Result Group
program, through failure to support the hospital tumor registry activities in Connecti-
cut, was unacceptable to the NCI, which had a substantial investment in the ERG.
Therefore, the NCI increased its support to the Connecticut registry, which now had
the legal right to require that cancer be reported to the State Health Department. It is
worthwhile noting that at this time, on the national scene, the 92nd Congress of the
U.S. passed a bill (H.R. 8343, H.R. 10681, S 1828) in 1971 to establish a National
Cancer Authority in order to conquer cancer at the earliet possible date. This bill was
entitled 'The National Cancer Attack Act of 1971' [31].
"Up to 1972, the relationship between the registry and NCI had been through
participation in the End Results Group. Before that time, the NCI had two distinct
programs for the collection of incidence and patient survival data. The End Results
Group supplied the survival data, while the incidence data had been collected through
cancer morbidity surveys. With the completion of the third national cancer morbidity
survey covering the years 1969-71 [32], it was obvious that the cancer morbidity
survey approach was inefficient and that it would be preferable to establish a network
of population-based cancer registries. The Connecticut Tumor Registry became a
participant in this network, which was established at the NCI in 1972 under the title
'Surveillance, Epidemiology, and End Results (SEER) Program.'
"A problem which reoccurred during this period was the inability ofthe Connecticut
Tumor Registry to recruit research staff. This situation called for other arrangements.
There was a need to combine the strong Connecticut registry capabilities in data
management with those ofan institution with a good research base. In Connecticut, the
two obvious candidates were the University of Connecticut School of Medicine and
Yale University. Yale was judged superior because of its ability to identify people who
could conduct epidemiologic research and who were in contact with physicians in the
state. There ensued exploratory negotiations concerning the feasibility of establishing
a Connecticut Cancer Epidemiology Unit (CCEU) at the Yale University Department
ofEpidemiology and Public Health. The outcome was that the work ofthe Connecticut
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registry and its research arm, the CCEU, was supported by two NCI contracts, one
with the State Department ofHealth and the other with Yale University. Dr. J. Wister
Meigs was appointed the first director of CCEU in 1974 [33]. In a recent paper, he
described the role ofthe Connecticut Tumor Registry during its fifty years ofservice in
assisting a large number ofcancer epidemiologists, both at home and abroad [34]."
The contracts and administrative relationships which existed between the NCI, the
Connecticut Tumor Registry, and the Connecticut Cancer Epidemiology Unit at Yale
were in force when Dr. W. Haenszel retired from the National Cancer Institute in
1976. In reminiscing, he states:
"My successor responsible for overall direction ofthe NCI's Surveillance, Epidemi-
ology, and End Results (SEER) Program and the Connecticut participation in this
program was none other than Dr. Earl Pollack, who was research statistician with the
Connecticut Registry in the 1950 decade. Thus, serendipity played a large role in the
development of the Connecticut Tumor Registry. It did not develop according to a
predesigned plan, but the people involved were able to take advantage ofopportunities
as they presented themselves. It can certainly be defended as a good example of close
cooperation between units in the state and federal governments that were able to pool
their resources and efforts to pursue a common goal."
In 1982, Dr. Meigs was succeeded by M.G. McCrea Curnen, M.D., Dr. P.H., who
became director of the CCEU and medical director of the Connecticut Tumor
Registry. She reported on the assistance which the Connecticut Tumor Registry offers
toward the development of cancer prevention programs [35]. Following a survey of
1,572 records from the Connecticut Tumor Registry, she also evaluated the usefulness
of epidemiologic data currently being collected on patients' occupation/industry,
smoking habits, and family history ofcancer. Criteria for usefulness ofthesedata were
based on their potential for standardization and statistical analysis [36]. In this study,
the rapidity with which hospitals report cancer cases to the Connecticut registry was
also investigated. The study found that 47.5 percent of cases had been reported to the
Connecticut Tumor Registry within three months ofdiagnosis, 77.5 percent within six
months, and 97.5 percent within one year. There was no evidence that hospital size
played a major role in the rapidity ofreporting, although small hospitals had a greater
number ofcases reported within three and six months than larger hospitals.
While the Connecticut Tumor Registry was dependent for data on the hospital
tumor clinic secretaries in the early years of its development, it now depends on the
hospital tumor registrars toprovide rapidly an increased amountofdata tothe registry.
Registrars, who are presently certified by the National Tumor Registrars Association,
are well trained and capable ofperforming a wide variety ofcancer data management
skills [37]. They play an important role in maintaining thequality and completeness of
data in the Connecticut Tumor Registry.
Dr. D. Janerich became director of the CCEU and Medical Director of the
Connecticut Tumor Registry in 1985. Heestablished, in the Department ofEpidemiol-
ogy and Public Health at Yale, the first Cancer Control Research Unit (CCRU) for
Connecticut, supported by the NCI, and the CCEU research arm ofthe tumor registry
was moved from New Haven to Hartford.
This new CCRU endeavor is developed around the Connecticut Tumor Registry,
which will require uninterrupted financial support. It will bring together investigators
from Yale University, the University of Connecticut, and the Connecticut State
Department of Health Services in an effort to devise and apply methods ofprevention
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for various types ofcancer. Among a number ofepidemiologic, clinical, and laboratory
projects, a statewide study will be undertaken during the 1986-1991 period aimed at
eradicating invasive cervical cancer, a disease which should be preventable at this time
[38].
This multidisciplinary effort to prevent cancer will require thecollaboration ofmany
investigators whose various skills will increase our understanding of the biology and
control ofthis disease.
A renewed emphasis on cancer control, both at home and abroad, will be featured in
the years ahead. These preventive programs will continue to utilize the resources ofthe
Connecticut Tumor Registry and add another chapter to its first fifty years ofvaluable
service.
ACKNOWLEDGEMENT
We thank Ms. Ann Marie Tears for her invaluable assistance in preparing this manuscript.
REFERENCES
1. The cancer problem in New Haven: Report of the Cancer Commitee Program, April 1930-December
1935, with a statistical analysis ofcancer morbidity and mortality 1920-1934. Orange, CT, The Wilson
H Lee Co, 1935
2. Connecticut State Medical Society, Proceedings. New Haven, CT, Connecticut State Medical Society,
1933
3. State ofConnecticut, Senate, Substitute for Senate Bill No. 101. 1935
4. McLellan PM: Association ofTumor Clinics. Conn State Med J 1 (2):100-113, 1936
5. Gershman ST, Flannery JT, Barrett H, Nadel RK, Meigs JW: Development ofthe Connecticut Tumor
Registry. Conn Med 40 (10):697-701, 1976
6. Breslow L: A history of Cancer Control in the United States 1946-1971. Book Two: A history of
programmatic developments in cancer control, DHEW Publication No (NIH) 79-1518. Washington,
DC, U.S. Government Printing Office, 1979, pp 511-513
7. Dorn HF: Illness from cancer in the United States. Publ Health Rep 59:33-48, 65-77, 97-115, 1944
8. Wynder EL,Graham EA: Tobacco smoking as a possible etiologic factor in bronchiogeniccarcinoma: A
study ofsix hundred eighty-four proved cases. JAMA 143:329-336, 1950
9. Doll R, Hill AB: Smoking and carcinoma ofthe lung: Preliminary report. Brit Med J 2:739-748, 1950
10. Connelly RR, Campbell PC, Eisenberg H: Central Registry ofcancer cases in Connecticut. Publ Health
Rep 83 (5):386-390, 1968
11. Eisenberg H, Campbell PC, Flannery JT: Cancer in Connecticut: Incidence characteristics 1935-62.
Hartford, CT, Conn State Dept Health, 1967
12. Heston JF, Kelly JB, Meigs JW, Flannery JT: Forty-five years of cancer incidence in Connecticut,
1935-1979. Natl Cancer Inst Monogr No. 70. Washington, DC, U.S. Government Printing Office,
1986
13. Ottenheimer EJ, Oughterson AW: Observations on cancer of the colon and rectum in Connecticut. An
analysis based on 5572 proved cases. New Eng J Med 252:561-567, 1955
14. Dorn HF, Cutler SJ: Morbidity from cancer in the United States. Publ Health Monogr No. 56. Publ
Health Serv Publ 590. Washington, DC, U.S. Government Printing Office, 1959
15. Griswold MH, Wilder CS, Cutler SJ, Pollack ES: Cancer in Connecticut, 1935-1951. Hartford, CT,
Conn State Dept Health, 1955
16. Bailar JC III, Loury R, Goldberg IS: A note on follow-ups oflost patients. In End Results and Mortality
Trends in Cancer. U.S. Dept of Health, Education, and Welfare. Natl Cancer Inst Monogr No. 6.
Washington, DC, U.S. Government Printing Office, 1961, pp 123-127
17. Bailar JC III, Thomas LB, Thomson AD, Eisenberg H, Vick RM: Morphology and survival rates of
cervical cancer in Connecticut and Southwest England. U.S. Dept of Health, Education, and Welfare.
Natl Cancer Inst Monogr No. 19. Washington, DC, U.S. Government Printing Office, 1965, pp
385-403
18. Axtell LM, Breslow L, Eisenberg H: Trends in survival rates of cancer patients: Connecticut and
California. In End Results and Mortality Trends in Cancer. U.S. Dept of Health, Education, and484 HAENSZEL AND CURNEN
Welfare. Natl Cancer Inst Monogr No. 6. Washington, DC, U.S. Government Printing Office, 1961, pp
49-67
19. Doll R, Payne P, Waterhouse J. (ed): Cancer Incidence in Five Continents. A Technical Report.
International Union Against Cancer. New York, Springer-Verlag Publishers, 1966
20. Berkson J, Gage RP: Calculation ofsurvival rates for cancer. Proc StaffMeet Mayo Clinic 25:270-286,
1950
21. Ederer F, Axtell LM, Cutler SJ: The relative survival rate: A statistical methodology. In End Results
and Mortality Trends in Cancer. U.S. Dept. of Health, Education, and Welfare, Natl Cancer Inst
Monogr No. 6. Washington DC, U.S. Government Printing Office, 1961, pp 101-121
22. Cutler SJ, Ederer F, Griswold MH, Greenberg RA: Survival of breast cancer patients in Connecticut,
1935-1954. J Natl Cancer Inst 23:1137-1156, 1959
23. Cutler SJ, Ederer F, Griswold MH, Greenberg RA: Survival of patients with uterine cancer,
1935-1954. J Natl Cancer Inst 24:519-539, 1960
24. Cutler SJ, Ederer F, Griswold MH, Greenberg RA: Survival of patients with ovarian cancer,
1935-1954. J Natl Cancer Inst 24:541-549, 1960
25. Eisenberg H, Cutler SJ, Axtell L: Differential survival ofcancer for selected sites. Achter Internation-
aler Kongress Fur Lebensversicherungsmedizin (Proc 8th International Congress of Life Assurance
Med) Luzern, Switzerland, 15-19 June 1964. Basel, Schwabe & Co Verlag, 1964, pp 121-134
26. Percy C, Berg LW, Thomas LB (ed): Manual ofTumor Nomenclature and Coding. American Cancer
Society, Inc, LB Thomas Publisher, 1968
27. Ederer F, Myers MH, Mantel N: A statistical problem in space and time: Do leukemia cases come in
clusters? Biometrics 20:626-638, 1964
28. Eisenberg H, Sullivan P, Connelly RR: Cancer in Connecticut. Survival Experience, 1935-1962.
Hartford, CT, Conn State Dept of Health, 1969
29. Christine BW, Sullivan PD, Connelly RR, Foote F: Cancer incidence, mortality and survival in
Connecticut during the 1960s. Conn Med 34 (8):564-569, 1970
30. State ofCommecticut, Administrative Regulations. Department of Health, 1971
31. National Cancer Attack Act of 1971. Part 1. Hearings before the subcommittee on public health and
environment of the Committee on interstate and foreign commerce, House of Representatives, 92nd
Congress. 1st Session on H.R. 8343, H.R. 10681, S. 1828 (and all other bills and resolutions). Serial No
92-40. Washington, DC, U.S. Government Printing Office, 1971, p 5
32. Cutler SJ, Young JL Jr: Third National Cancer Survey; Incidence data. U.S. Dept of Health,
Education, and Welfare. Natl Cancer Inst Monogr No. 41. Washington, DC, U.S. Government Printing
Office, 1975, pp 1-454
33. Meigs JW: The Connecticut Cancer Epidemiology Unit. Conn Med 39 (10):637-640, 1975
34. Meigs JW: The impact of the Connecticut Tumor Registry on cancer epidemiology. Conn Med 49
(11):742-746, 1985
35. Curnen MG McCrea, Thompson WD, Heston JF, Flannery JT: Cancer prevention: The Tumor
Registry connection. Cancer Detect Prev 7:191-199, 1984
36. Curnen MG McCrea, Thompson WD, Flannery JT: The Connecticut Tumor Registry: Potential for
increasing its usefulness in etiologic research. Conn Med 49 (11):753-759, 1985
37. Hurst MC: The Tumor Registrar: Past, present, future. Conn Med 49 (11):737-740, 1985
38. Janerich DT, Hadjimichael 0, Flannery JT: Strategy for elimination of invasive cervical cancer in
Connecticut. Conn Med 49 (11):746-753, 1985